EGFR Positive Lung Cancer UK
@egfrpositiveuk.bsky.social
The only UK charity for EGFR+ lung cancer advocacy, empowerment & support 💜
Our community offers hope & learning for those living with EGFR+.
Get involved → linktr.ee/egfrpositivelungcanceruk
Our community offers hope & learning for those living with EGFR+.
Get involved → linktr.ee/egfrpositivelungcanceruk
🚴♀️ Mel, amazing member of our EGFR+ UK community, appeared on BBC Breakfast this morning alongside Sir Chris Hoy to talk about #TourDe4 & living with stage 4 #lungcancer.
She shared her story, her strength, & why this ride matters.
📺 Watch here: youtu.be/HqGqmuL5Q7E
#EGFRPositive #LCSM
She shared her story, her strength, & why this ride matters.
📺 Watch here: youtu.be/HqGqmuL5Q7E
#EGFRPositive #LCSM
June 2, 2025 at 2:37 PM
🚴♀️ Mel, amazing member of our EGFR+ UK community, appeared on BBC Breakfast this morning alongside Sir Chris Hoy to talk about #TourDe4 & living with stage 4 #lungcancer.
She shared her story, her strength, & why this ride matters.
📺 Watch here: youtu.be/HqGqmuL5Q7E
#EGFRPositive #LCSM
She shared her story, her strength, & why this ride matters.
📺 Watch here: youtu.be/HqGqmuL5Q7E
#EGFRPositive #LCSM
Looking forward @lungcancereurope.bsky.social’s AGM in Berlin next week. It’s a tremendous opportunity to work cohesively across Europe bringing synergies in patient advocacy.
We’re particularly interested to take part in the masterclass on AI for #lungcancer patient advocacy. #LCSM
We’re particularly interested to take part in the masterclass on AI for #lungcancer patient advocacy. #LCSM
April 4, 2025 at 8:36 AM
Looking forward @lungcancereurope.bsky.social’s AGM in Berlin next week. It’s a tremendous opportunity to work cohesively across Europe bringing synergies in patient advocacy.
We’re particularly interested to take part in the masterclass on AI for #lungcancer patient advocacy. #LCSM
We’re particularly interested to take part in the masterclass on AI for #lungcancer patient advocacy. #LCSM
Natasha Loveridge steps down as Marketing Trustee of EGFR+ UK after 18 impactful months. Known for her relentless energy & warmth, Natasha has significantly raised awareness about #lungcancer in non-smokers.
While stepping back we’re grateful she remains a key part of our team. 🙏 Natasha! #LCSM
While stepping back we’re grateful she remains a key part of our team. 🙏 Natasha! #LCSM
April 1, 2025 at 7:12 AM
Natasha Loveridge steps down as Marketing Trustee of EGFR+ UK after 18 impactful months. Known for her relentless energy & warmth, Natasha has significantly raised awareness about #lungcancer in non-smokers.
While stepping back we’re grateful she remains a key part of our team. 🙏 Natasha! #LCSM
While stepping back we’re grateful she remains a key part of our team. 🙏 Natasha! #LCSM
New data from the LAURA trial shared at #ELCC25 today shows promising results for Stage 3 unresectable EGFR+ #lungcancer.
Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM
Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM
March 28, 2025 at 5:38 PM
New data from the LAURA trial shared at #ELCC25 today shows promising results for Stage 3 unresectable EGFR+ #lungcancer.
Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM
Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM
Just presented at #ELCC25:
MARIPOSA confirms a survival benefit—amivantamab + lazertinib shows a 25% OS advantage (60% alive at 3 years) vs osimertinib in advanced EGFR+ #lungcancer.
A breakthrough—but people in the UK are still waiting for access.
#LCSM
MARIPOSA confirms a survival benefit—amivantamab + lazertinib shows a 25% OS advantage (60% alive at 3 years) vs osimertinib in advanced EGFR+ #lungcancer.
A breakthrough—but people in the UK are still waiting for access.
#LCSM
March 26, 2025 at 4:40 PM
Just presented at #ELCC25:
MARIPOSA confirms a survival benefit—amivantamab + lazertinib shows a 25% OS advantage (60% alive at 3 years) vs osimertinib in advanced EGFR+ #lungcancer.
A breakthrough—but people in the UK are still waiting for access.
#LCSM
MARIPOSA confirms a survival benefit—amivantamab + lazertinib shows a 25% OS advantage (60% alive at 3 years) vs osimertinib in advanced EGFR+ #lungcancer.
A breakthrough—but people in the UK are still waiting for access.
#LCSM
Yesterday EGFR+ UK trustees met for a full strategy day.
We worked through priorities for the year ahead, all with one goal in mind: improving outcomes for people with EGFR+ #lungcancer.
Thanks to Angela, Gini, Soumitra, Natasha & Liz for their energy, focus & commitment 💜. #LCSM
We worked through priorities for the year ahead, all with one goal in mind: improving outcomes for people with EGFR+ #lungcancer.
Thanks to Angela, Gini, Soumitra, Natasha & Liz for their energy, focus & commitment 💜. #LCSM
March 26, 2025 at 7:55 AM
Yesterday EGFR+ UK trustees met for a full strategy day.
We worked through priorities for the year ahead, all with one goal in mind: improving outcomes for people with EGFR+ #lungcancer.
Thanks to Angela, Gini, Soumitra, Natasha & Liz for their energy, focus & commitment 💜. #LCSM
We worked through priorities for the year ahead, all with one goal in mind: improving outcomes for people with EGFR+ #lungcancer.
Thanks to Angela, Gini, Soumitra, Natasha & Liz for their energy, focus & commitment 💜. #LCSM
MARIPOSA shows a 25% OS benefit for amivantamab + lazertinib vs osimertinib in newly diagnosed EGFR+ advanced #lungcancer.
A big moment—but not simple. Side effects, IV treatment & QoL all matter.
& right now, this option isn’t available for our UK EGFR+ community.
Full results at #ELCC25 #LCSM
A big moment—but not simple. Side effects, IV treatment & QoL all matter.
& right now, this option isn’t available for our UK EGFR+ community.
Full results at #ELCC25 #LCSM
March 24, 2025 at 9:42 AM
MARIPOSA shows a 25% OS benefit for amivantamab + lazertinib vs osimertinib in newly diagnosed EGFR+ advanced #lungcancer.
A big moment—but not simple. Side effects, IV treatment & QoL all matter.
& right now, this option isn’t available for our UK EGFR+ community.
Full results at #ELCC25 #LCSM
A big moment—but not simple. Side effects, IV treatment & QoL all matter.
& right now, this option isn’t available for our UK EGFR+ community.
Full results at #ELCC25 #LCSM
After Christine passed away in Oct 2024, her husband Sean met with her GP surgery to discuss her delayed EGFR+ #lungcancer diagnosis.
Now, Banbury Cross Health Centre has made lung cancer in non-smokers part of their GP training.
💬 Patient advocacy changes conversations & outcomes. #LCSM
Now, Banbury Cross Health Centre has made lung cancer in non-smokers part of their GP training.
💬 Patient advocacy changes conversations & outcomes. #LCSM
March 20, 2025 at 8:13 AM
After Christine passed away in Oct 2024, her husband Sean met with her GP surgery to discuss her delayed EGFR+ #lungcancer diagnosis.
Now, Banbury Cross Health Centre has made lung cancer in non-smokers part of their GP training.
💬 Patient advocacy changes conversations & outcomes. #LCSM
Now, Banbury Cross Health Centre has made lung cancer in non-smokers part of their GP training.
💬 Patient advocacy changes conversations & outcomes. #LCSM
NEW Nature Medicine study: Molecular residual disease (MRD) in EGFR+ #lungcancer could help predict recurrence & guide future treatment strategies. #LCSM
www.nature.com/articles/s41...
www.nature.com/articles/s41...
March 18, 2025 at 8:22 AM
NEW Nature Medicine study: Molecular residual disease (MRD) in EGFR+ #lungcancer could help predict recurrence & guide future treatment strategies. #LCSM
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Amanda Procter from Maggie’s Yorkshire joined our EGFR+ UK #lungcancer community to discuss how @maggiescentres.bsky.social offer emotional, psychological, & practical support alongside NHS care.
Watch the full conversation & more ‘Meet the Expert’ sessions: www.egfrpositive.org.uk/videos 💜 #LCSM
Watch the full conversation & more ‘Meet the Expert’ sessions: www.egfrpositive.org.uk/videos 💜 #LCSM
March 17, 2025 at 8:23 AM
Amanda Procter from Maggie’s Yorkshire joined our EGFR+ UK #lungcancer community to discuss how @maggiescentres.bsky.social offer emotional, psychological, & practical support alongside NHS care.
Watch the full conversation & more ‘Meet the Expert’ sessions: www.egfrpositive.org.uk/videos 💜 #LCSM
Watch the full conversation & more ‘Meet the Expert’ sessions: www.egfrpositive.org.uk/videos 💜 #LCSM
Today is #NationalCancerCNSDay, and we want to say a massive thank you💜
For those of us with EGFR+ #lungcancer, CNSs are a lifeline. They listen, reassure, and fight for us when it matters most. We quite simply couldn’t do this without you! #LCSM
For those of us with EGFR+ #lungcancer, CNSs are a lifeline. They listen, reassure, and fight for us when it matters most. We quite simply couldn’t do this without you! #LCSM
March 14, 2025 at 7:38 AM
Today is #NationalCancerCNSDay, and we want to say a massive thank you💜
For those of us with EGFR+ #lungcancer, CNSs are a lifeline. They listen, reassure, and fight for us when it matters most. We quite simply couldn’t do this without you! #LCSM
For those of us with EGFR+ #lungcancer, CNSs are a lifeline. They listen, reassure, and fight for us when it matters most. We quite simply couldn’t do this without you! #LCSM
📊 40% of #lungcancer patients say they didn’t get enough details about their diagnosis.*
📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.**
Patients can’t make informed choices without the right info. #LCSM
* LuCE 9th Report
** EGFR+ UK member survey
📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.**
Patients can’t make informed choices without the right info. #LCSM
* LuCE 9th Report
** EGFR+ UK member survey
March 11, 2025 at 8:31 AM
📊 40% of #lungcancer patients say they didn’t get enough details about their diagnosis.*
📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.**
Patients can’t make informed choices without the right info. #LCSM
* LuCE 9th Report
** EGFR+ UK member survey
📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.**
Patients can’t make informed choices without the right info. #LCSM
* LuCE 9th Report
** EGFR+ UK member survey
Health equality doesn’t just happen—it takes people speaking up, pushing for better & refusing to accept less.
Today, on #InternationalWomenDay, we’re recognising the women driving change in EGFR+ #lungcancer & beyond. Your determination, resilience & advocacy make a difference every day 🙏.
#LCSM
Today, on #InternationalWomenDay, we’re recognising the women driving change in EGFR+ #lungcancer & beyond. Your determination, resilience & advocacy make a difference every day 🙏.
#LCSM
March 8, 2025 at 9:11 AM
Health equality doesn’t just happen—it takes people speaking up, pushing for better & refusing to accept less.
Today, on #InternationalWomenDay, we’re recognising the women driving change in EGFR+ #lungcancer & beyond. Your determination, resilience & advocacy make a difference every day 🙏.
#LCSM
Today, on #InternationalWomenDay, we’re recognising the women driving change in EGFR+ #lungcancer & beyond. Your determination, resilience & advocacy make a difference every day 🙏.
#LCSM
Grateful to have these brilliant oncologists in our corner!
They help us push for better EGFR+ #lungcancer care - keep up with research, drive access to treatment, & support our community.
Dr Riyaz Shah, Dr Shobhit Baijal, Dr Alex Georgiou, Dr Yvonne Summers (from top left).
Thank you! 🙏 #LCSM
They help us push for better EGFR+ #lungcancer care - keep up with research, drive access to treatment, & support our community.
Dr Riyaz Shah, Dr Shobhit Baijal, Dr Alex Georgiou, Dr Yvonne Summers (from top left).
Thank you! 🙏 #LCSM
March 6, 2025 at 7:50 AM
Grateful to have these brilliant oncologists in our corner!
They help us push for better EGFR+ #lungcancer care - keep up with research, drive access to treatment, & support our community.
Dr Riyaz Shah, Dr Shobhit Baijal, Dr Alex Georgiou, Dr Yvonne Summers (from top left).
Thank you! 🙏 #LCSM
They help us push for better EGFR+ #lungcancer care - keep up with research, drive access to treatment, & support our community.
Dr Riyaz Shah, Dr Shobhit Baijal, Dr Alex Georgiou, Dr Yvonne Summers (from top left).
Thank you! 🙏 #LCSM
Prof. Gini Harrison & Charlie Maxwell will represent us at #BTOG25 engaging with the latest in #lungcancer research & advocacy.
We’ll be raising awareness of #EGFR+ & the support we offer, while sharing a table with our friends @alkpositiveuk.bsky.social
If you’re there, do say hi! #LCSM
We’ll be raising awareness of #EGFR+ & the support we offer, while sharing a table with our friends @alkpositiveuk.bsky.social
If you’re there, do say hi! #LCSM
March 3, 2025 at 7:32 AM
Prof. Gini Harrison & Charlie Maxwell will represent us at #BTOG25 engaging with the latest in #lungcancer research & advocacy.
We’ll be raising awareness of #EGFR+ & the support we offer, while sharing a table with our friends @alkpositiveuk.bsky.social
If you’re there, do say hi! #LCSM
We’ll be raising awareness of #EGFR+ & the support we offer, while sharing a table with our friends @alkpositiveuk.bsky.social
If you’re there, do say hi! #LCSM
“The Princess of Wales seemed genuinely interested & like many people was unaware you can get #lungcancer even if you’ve never smoked.”
Angela Terry shares more about her meeting with royalty in our latest newsletter. It’s not too late to sign up to get it tomorrow! #LCSM
👉 shorturl.at/SS5Fd
Angela Terry shares more about her meeting with royalty in our latest newsletter. It’s not too late to sign up to get it tomorrow! #LCSM
👉 shorturl.at/SS5Fd
February 28, 2025 at 11:26 AM
“The Princess of Wales seemed genuinely interested & like many people was unaware you can get #lungcancer even if you’ve never smoked.”
Angela Terry shares more about her meeting with royalty in our latest newsletter. It’s not too late to sign up to get it tomorrow! #LCSM
👉 shorturl.at/SS5Fd
Angela Terry shares more about her meeting with royalty in our latest newsletter. It’s not too late to sign up to get it tomorrow! #LCSM
👉 shorturl.at/SS5Fd
Our next ‘Meet the Expert’ session 💜
On 4th Mar 11am, Amanda Procter from Maggie’s Yorks will be talking to our #EGFR+ #lungcancer community about the support @maggiescentres.bsky.social provides for those with cancer.
It’s an online session - Zoom details in our closed support group. #LCSM
On 4th Mar 11am, Amanda Procter from Maggie’s Yorks will be talking to our #EGFR+ #lungcancer community about the support @maggiescentres.bsky.social provides for those with cancer.
It’s an online session - Zoom details in our closed support group. #LCSM
February 24, 2025 at 11:38 AM
Our next ‘Meet the Expert’ session 💜
On 4th Mar 11am, Amanda Procter from Maggie’s Yorks will be talking to our #EGFR+ #lungcancer community about the support @maggiescentres.bsky.social provides for those with cancer.
It’s an online session - Zoom details in our closed support group. #LCSM
On 4th Mar 11am, Amanda Procter from Maggie’s Yorks will be talking to our #EGFR+ #lungcancer community about the support @maggiescentres.bsky.social provides for those with cancer.
It’s an online session - Zoom details in our closed support group. #LCSM
A look at what lung cancer can learn from chronic myeloid leukemia—how its treatment advances could shape targeted therapy & resistance management in EGFR+ #lungcancer. #LCSM
🔗 jamanetwork.com/journals/jam...
🔗 jamanetwork.com/journals/jam...
February 23, 2025 at 9:23 AM
A look at what lung cancer can learn from chronic myeloid leukemia—how its treatment advances could shape targeted therapy & resistance management in EGFR+ #lungcancer. #LCSM
🔗 jamanetwork.com/journals/jam...
🔗 jamanetwork.com/journals/jam...
Huge 🙏 to Sara & other EGFR+ UK members who are getting these #lungcancer awareness posters into GP waiting rooms, pharmacies & gyms.
This is what grassroots awareness looks like—real people making a real impact. 💜
Lung cancer can happen to anyone - early recognition of symptoms is crucial. #LCSM
This is what grassroots awareness looks like—real people making a real impact. 💜
Lung cancer can happen to anyone - early recognition of symptoms is crucial. #LCSM
February 19, 2025 at 7:30 AM
Huge 🙏 to Sara & other EGFR+ UK members who are getting these #lungcancer awareness posters into GP waiting rooms, pharmacies & gyms.
This is what grassroots awareness looks like—real people making a real impact. 💜
Lung cancer can happen to anyone - early recognition of symptoms is crucial. #LCSM
This is what grassroots awareness looks like—real people making a real impact. 💜
Lung cancer can happen to anyone - early recognition of symptoms is crucial. #LCSM
EGFR+ doesn’t fit the usual profile - that leads to late diagnosis.
1/2 are < 60
3/4 at Stage 4
Most are women
68% never smoked
Symptoms get dismissed, referrals delayed & #lungcancer isn’t considered until everything else is ruled out. By then, it’s Stage 4.
Stats: EGFR+ UK member survey. #LCSM
1/2 are < 60
3/4 at Stage 4
Most are women
68% never smoked
Symptoms get dismissed, referrals delayed & #lungcancer isn’t considered until everything else is ruled out. By then, it’s Stage 4.
Stats: EGFR+ UK member survey. #LCSM
February 17, 2025 at 1:02 PM
EGFR+ doesn’t fit the usual profile - that leads to late diagnosis.
1/2 are < 60
3/4 at Stage 4
Most are women
68% never smoked
Symptoms get dismissed, referrals delayed & #lungcancer isn’t considered until everything else is ruled out. By then, it’s Stage 4.
Stats: EGFR+ UK member survey. #LCSM
1/2 are < 60
3/4 at Stage 4
Most are women
68% never smoked
Symptoms get dismissed, referrals delayed & #lungcancer isn’t considered until everything else is ruled out. By then, it’s Stage 4.
Stats: EGFR+ UK member survey. #LCSM
Our 2024 survey showed #EGFR+ #lungcancer patients face immense mental & emotional challenges, ＞1/4 likely have diagnosable depression. We can't provide direct crisis support, but we've launched a new directory to guide patients to the support they need 💜 egfrpositive.org.uk/crisis-support #LCSM
February 13, 2025 at 7:09 AM
Our 2024 survey showed #EGFR+ #lungcancer patients face immense mental & emotional challenges, ＞1/4 likely have diagnosable depression. We can't provide direct crisis support, but we've launched a new directory to guide patients to the support they need 💜 egfrpositive.org.uk/crisis-support #LCSM
Almost 1/2 of those affected by #lungcancer know little about clinical trials. But they can offer access to new treatment options & hope.
Anne-Marie Baird explains:
🔍 What trials are
📋 How to qualify
💊 EGFR drugs in trials
In our lastest ‘meet the expert’ session
📽️ egfrpositive.org.uk/videos #lcsm
Anne-Marie Baird explains:
🔍 What trials are
📋 How to qualify
💊 EGFR drugs in trials
In our lastest ‘meet the expert’ session
📽️ egfrpositive.org.uk/videos #lcsm
February 11, 2025 at 11:46 AM
Almost 1/2 of those affected by #lungcancer know little about clinical trials. But they can offer access to new treatment options & hope.
Anne-Marie Baird explains:
🔍 What trials are
📋 How to qualify
💊 EGFR drugs in trials
In our lastest ‘meet the expert’ session
📽️ egfrpositive.org.uk/videos #lcsm
Anne-Marie Baird explains:
🔍 What trials are
📋 How to qualify
💊 EGFR drugs in trials
In our lastest ‘meet the expert’ session
📽️ egfrpositive.org.uk/videos #lcsm
Looking for the latest #EGFR+ #lungcancer updates?
Join our thriving email community.
Updates every 2 months with research developments, support resources, & event news - plus exclusive bulletins on the news that matters most.
Next issue out end of Feb. #lcsm
mailchi.mp/egfrpositive...
Join our thriving email community.
Updates every 2 months with research developments, support resources, & event news - plus exclusive bulletins on the news that matters most.
Next issue out end of Feb. #lcsm
mailchi.mp/egfrpositive...
February 9, 2025 at 8:03 AM
Looking for the latest #EGFR+ #lungcancer updates?
Join our thriving email community.
Updates every 2 months with research developments, support resources, & event news - plus exclusive bulletins on the news that matters most.
Next issue out end of Feb. #lcsm
mailchi.mp/egfrpositive...
Join our thriving email community.
Updates every 2 months with research developments, support resources, & event news - plus exclusive bulletins on the news that matters most.
Next issue out end of Feb. #lcsm
mailchi.mp/egfrpositive...
Every day, 20 people in the UK are told they have #EGFR+ #lungcancer.
No one should have to face that alone. That’s why we’re here—to offer support, raise awareness, and push for earlier diagnosis.
Please support us with a donation if you can 💜 www.egfrpositive.org.uk/donate
#LCSM
No one should have to face that alone. That’s why we’re here—to offer support, raise awareness, and push for earlier diagnosis.
Please support us with a donation if you can 💜 www.egfrpositive.org.uk/donate
#LCSM
January 31, 2025 at 7:27 AM
Every day, 20 people in the UK are told they have #EGFR+ #lungcancer.
No one should have to face that alone. That’s why we’re here—to offer support, raise awareness, and push for earlier diagnosis.
Please support us with a donation if you can 💜 www.egfrpositive.org.uk/donate
#LCSM
No one should have to face that alone. That’s why we’re here—to offer support, raise awareness, and push for earlier diagnosis.
Please support us with a donation if you can 💜 www.egfrpositive.org.uk/donate
#LCSM
For people with #lungcancer, improving muscle strength can cut the risk of dying by 19% & cardiorespiratory fitness can lower it by 31%.
Exercise boosts QoL & improves overall survival. Even small steps—like building strength and fitness—can make a difference. #LCSM
bjsm.bmj.com/content/bjsp...
Exercise boosts QoL & improves overall survival. Even small steps—like building strength and fitness—can make a difference. #LCSM
bjsm.bmj.com/content/bjsp...
January 22, 2025 at 1:53 PM
For people with #lungcancer, improving muscle strength can cut the risk of dying by 19% & cardiorespiratory fitness can lower it by 31%.
Exercise boosts QoL & improves overall survival. Even small steps—like building strength and fitness—can make a difference. #LCSM
bjsm.bmj.com/content/bjsp...
Exercise boosts QoL & improves overall survival. Even small steps—like building strength and fitness—can make a difference. #LCSM
bjsm.bmj.com/content/bjsp...